Cardiac Insight is preparing for the launch of its CardeaScreen technology, and the company has raised $2.5 million to help spur adoption of its product.
The Kirkland, Wash.-based company’s 12-lead electrocardiogram helps identify young athletes who may be at risk for sudden cardiac arrest before getting out on the field. By using a diagnostic algorithm, the company can cut down on false positives.
The company will use the funds raised in this Series C round to market the new technology and move forward with a wearable sensor technology as well. The company declined to name the investors in this round of funding, but Cardiac Insight previously raised $7 million from Welch Allyn.
The company was founded in 2008 after being spun out of the University of Washington, based on research by UW cardiologist David Linker. Linker teamed up with serial medical device entrepreneur Brad Harlow, who serves as CEO at the biotech company.